Antioxidant therapy for atrial fibrillation: lost in translation?
نویسندگان
چکیده
منابع مشابه
Antioxidant therapy for atrial fibrillation: lost in translation?
Despite considerable evidence suggesting a central role for oxidative stress in pathogenesis of atrial fibrillation (AF), use of conventional reactive oxygen species (ROS) scavengers have not shown impressive results. ROS are a wide range of highly active molecules that can react quickly with their local surroundings. This characteristic may be part of the reason that general antioxidants have ...
متن کاملAntioxidant Therapy for Atrial Fibrillation: What Is the Next Step?
I read with interest the timely article by Rasoli and colleagues, who reviewed the literature on the efficacy of antioxidant vitamins in the management of atrial fibrillation (AF) [1]. Those authors emphasized an important clinical issue: despite considerable evidence of the role of oxidative stress in the pathogenesis of AF, antioxidant vitamins have not been shown to exert an impressive antia...
متن کاملAtrial Fibrillation Antiarrhythmic Drug Therapy for Atrial Fibrillation
Antiarrhythmic medications have been available for nearly 100 years and remain a mainstay in the management of atrial fibrillation (AF). Goals of therapy with the use of these drugs include a reduction in the frequency and duration of episodes of arrhythmia as well an emerging goal of reducing mortality and hospitalizations associated with AF. The use of these drugs has been limited by both pro...
متن کاملPacing therapy for atrial fibrillation.
Atrial fibrillation is the most common occurring clinical arrhythmia, often resulting in cerebral embolism and a deterioration of hemodynamics. According to the Framingham study, the incidence of atrial fibrillation is 0.5% in the fifties age group and rapidly increases to 8.8% in association with aging in people in their eighties .Many therapeutic methods have been proposed for atrial fibrilla...
متن کاملAntithrombotic therapy for atrial fibrillation.
Pooled estimate 1 2.5 (1.8-3.5) .59 (for heterogeneity) Studies included in pooled estimate: AFI 2/ 1994 2.5 (NR) , .05 SPAF I-III Aspirin 3/ 1999 2.9 (NR) , .001 Stöllberger et al 4 /1998 3.7 (1.5-7.5) .002 Wang et al 5 /2003 1.9 (1.1-3.3) NR Studies not included in pooled estimate: AFI Echo 6 /1998a 3.5 (1.8-6.7) , .001 Aronow et al 7 /1998 1.6 (1.1-2.2) , .009 Hart et al 8 /2000 (intermitten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heart
سال: 2012
ISSN: 1355-6037,1468-201X
DOI: 10.1136/heartjnl-2012-302328